Molecular MRI of Atherosclerosis

Current Cardiovascular Imaging Reports

Volumn 3, Issue 1, 2010, Pages 4-11

  Young, Victoria E L ^a   Tang, Tjun Y ^a   Sadat, Umar ^a   Gillard, Jonathan H ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Atheroma; Atherosclerosis; Carotid; Contrast; Molecular imaging; MRI

Indexed keywords

EID: 79957865161     PISSN: 19419066     EISSN: 19419074     Source Type: Journal    
DOI: 10.1007/s12410-010-9006-z     Document Type: Review

References (50)

1. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 2002, 105: 1135-1143.
2. Libby P: The molecular mechanisms of the thrombotic complications of atherosclerosis. J Intern Med 2008, 263: 517-527.
3. Loftus IM, Naylor AR, Bell PR, Thompson MM: Matrix metalloproteinases and atherosclerotic plaque instability. Br J Surg 2002, 89: 680-694.
4. Ruehm SG, Corot C, Vogt P, et al.: Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation 2001, 103: 415-422.
5. Yancy AD, Olzinski AR, Hu TC, et al.: Differential uptake of ferumoxtran-10 and ferumoxytol, ultrasmall superparamagnetic iron oxide contrast agents in rabbit: critical determinants of atherosclerotic plaque labeling. J Magn Reson Imaging 2005, 21: 432-442.
6. Herborn CU, Vogt FM, Lauenstein TC, et al.: Magnetic resonance imaging of experimental atherosclerotic plaque: comparison of two ultrasmall superparamagnetic particles of iron oxide. J Magn Reson Imaging 2006, 24: 388-393.
7. Hyafil F, Laissy JP, Mazighi M, et al.: Ferumoxtran-10-enhanced MRI of the hypercholesterolemic rabbit aorta: relationship between signal loss and macrophage infiltration. Arterioscler Thromb Vasc Biol 2006, 26: 176-181.
8. Trivedi RA, Mallawarachi CU, King-Im JM, et al.: Identifying inflamed carotid plaques using in vivo USPIO-enhanced MR imaging to label plaque macrophages. Arterioscler Thromb Vasc Biol 2006, 26: 1601-1606.
9. Kooi ME, Cappendijk VC, Cleutjens KB, et al.: Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 2003, 107: 2453-2458.
10. Trivedi RA, U-King-IM JM, Graves MJ, et al.: In vivo detection of macrophages in human carotid atheroma: temporal dependence of ultrasmall superparamagnetic particles of iron oxide-enhanced MRI. Stroke 2004, 35: 1631-1635.
11. Howarth SP, Tang TY, Trivedi R, et al.: Utility of USPIO-enhanced MR imaging to identify inflammation and the fibrous cap: a comparison of symptomatic and asymptomatic individuals. Eur J Radiol 2009, 70: 555-560.
12. Tang TY, Howarth SP, Miller SR, et al.: Comparison of the inflammatory burden of truly asymptomatic carotid atheroma with atherosclerotic plaques contralateral to symptomatic carotid stenosis: an ultra small superparamagnetic iron oxide enhanced magnetic resonance study. J Neurol Neurosurg Psychiatry 2007, 78: 1337-1343.
13. Tang TY, Patterson AJ, Miller SR, et al.: Temporal dependence of in vivo USPIO-enhanced MRI signal changes in human carotid atheromatous plaques. Neuroradiology 2009, 51: 457-465.
14. Tang T, Howarth SP, Miller SR, et al.: Assessment of inflammatory burden contralateral to the symptomatic carotid stenosis using high-resolution ultrasmall, superparamagnetic iron oxide-enhanced MRI. Stroke 2006, 37: 2266-2270.
15. Crowe L: Ex vivo MR imaging of atherosclerotic rabbit aorta labelled with USPIO: enhancement of iron loaded regions in UTE imaging. Proc Int Soc Mag Reson Med 2005, 13: 115.
16. • Tang TY, Howarth SP, Miller SR, et al.: The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. J Am Coll Cardiol 2009, 53: 2039-2050. This article demonstrates the impact these techniques can have on disease assessment and monitoring within a short timescale.
17. Mani V, Briley-Saebo KC, Itskovich VV, et al.: Gradient echo acquisition for superparamagnetic particles with positive contrast (GRASP): sequence characterization in membrane and glass superparamagnetic iron oxide phantoms at 1. 5T and 3T. Magn Reson Med 2006, 55: 126-135.
18. Saleh A, Schroeter M, Jonkmanns C, et al.: In vivo MRI of brain inflammation in human ischaemic stroke. Brain 2004, 127: 1670-1677.
19. Frias JC, Williams KJ, Fisher EA, Fayad ZA: Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc 2004, 126: 16316-16317.
20. Cormode DP, Chandrasekar R, Delshad A, et al.: Comparison of synthetic high density lipoprotein (HDL) contrast agents for MR imaging of atherosclerosis. Bioconjug Chem 2009, 20: 937-943.
21. Chen W, Vucic E, Leupold E, et al.: Incorporation of an apoE-derived lipopeptide in high-density lipoprotein MRI contrast agents for enhanced imaging of macrophages in atherosclerosis. Contrast Media Mol Imaging 2008, 3: 233-242.
22. Li H, Gray BD, Corbin I, et al.: MR and fluorescent imaging of low-density lipoprotein receptors. Acad Radiol 2004, 11: 1251-1259.
23. Nahrendorf M, Jaffer FA, Kelly KA, et al.: Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation 2006, 114: 1504-1511.
24. Tsourkas A, Shinde-Patil VR, Kelly KA, et al.: In vivo imaging of activated endothelium using an anti-VCAM-1 magneto-optical probe. Bioconjug Chem 2005, 16: 576-581.
25. Radermacher KA, Beghein N, Boutry S, et al.: In vivo detection of inflammation using pegylated iron oxide particles targeted at E-selectin: a multimodal approach using MR imaging and EPR spectroscopy. Invest Radiol 2009, 44: 398-404.
26. Boutry S, Laurent S, Elst LV, Muller RN: Specific E-selectin targeting with a superparamagnetic MRI contrast agent. Contrast Media Mol Imaging 2006, 1: 15-22.
27. Gustafsson B, Youens S, Louie AY: Development of contrast agents targeted to macrophage scavenger receptors for MRI of vascular inflammation. Bioconjug Chem 2006, 17: 538-547.
28. Mulder WJ, Strijkers GJ, Briley-Saboe KC, et al.: Molecular imaging of macrophages in atherosclerotic plaques using bimodal PEG-micelles. Magn Reson Med 2007, 58: 1164-1170.
29. Lipinski MJ, Frias JC, Amirbekian V, et al.: Macrophage-specific lipid-based nanoparticles improve cardiac magnetic resonance detection and characterization of human atherosclerosis. JACC Cardiovasc Imaging 2009, 2: 637-647.
30. Lipinski MJ, Amirbekian V, Frias JC, et al.: MRI to detect atherosclerosis with gadolinium-containing immunomicelles targeting the macrophage scavenger receptor. Magn Reson Med 2006, 56: 601-610.
31. Amirbekian V, Lipinski MJ, Briley-Saebo KC, et al.: Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc Natl Acad Sci U S A 2007, 104: 961-966.
32. Ronald JA, Chen JW, Chen Y, et al.: Enzyme-sensitive magnetic resonance imaging targeting myeloperoxidase identifies active inflammation in experimental rabbit atherosclerotic plaques. Circulation 2009, 120: 592-599.
33. Amirbekian V, Aguinaldo JG, Amirbekian S, et al.: Atherosclerosis and matrix metalloproteinases: experimental molecular MR imaging in vivo. Radiology 2009, 251: 429-438.
34. Burtea C, Laurent S, Lancelot E, et al.: Peptidic targeting of phosphatidylserine for the MRI detection of apoptosis in atherosclerotic plaques. Mol Pharm 2009, 6: 1903-1919.
35. Smith BR, Heverhagen J, Knopp M, et al.: Localization to atherosclerotic plaque and biodistribution of biochemically derivatized superparamagnetic iron oxide nanoparticles (SPIONs) contrast particles for magnetic resonance imaging (MRI). Biomed Microdevices 2007, 9: 719-727.
36. van Tilborg GA, Mulder WJ, Chin PT, et al.: Annexin A5-conjugated quantum dots with a paramagnetic lipidic coating for the multimodal detection of apoptotic cells. Bioconjug Chem 2006, 17: 865-868.
37. von Zur Muhlen C, von Elverfeldt D, Bassler N, et al.: Superparamagnetic iron oxide binding and uptake as imaged by magnetic resonance is mediated by the integrin receptor Mac-1 (CD11b/CD18): implications on imaging of atherosclerotic plaques. Atherosclerosis 2007, 193: 102-111.
38. Cyrus T, Abendschein DR, Caruthers SD, et al.: MR three-dimensional molecular imaging of intramural biomarkers with targeted nanoparticles. J Cardiovasc Magn Reson 2006, 8: 535-541.
39. Anderson SA, Rader RK, Westlin WF, et al.: Magnetic resonance contrast enhancement of neovasculature with alpha(v)beta(3)-targeted nanoparticles. Magn Reson Med 2000, 44: 433-439.
40. Langheinrich AC, Kampschulte M, Buch T, Bohle RM: Vasa vasorum and atherosclerosis-quid novi? Thromb Haemost 2007, 97: 873-879.
41. Mulder WJ, Castermans K, van Beijnum JR, et al.: Molecular imaging of tumor angiogenesis using alphavbeta3-integrin targeted multimodal quantum dots. Angiogenesis 2009, 12: 17-24.
42. Botnar RM, Perez AS, Witte S, et al.: In vivo molecular imaging of acute and subacute thrombosis using a fibrin-binding magnetic resonance imaging contrast agent. Circulation 2004, 109: 2023-2029.
43. Botnar RM, Buecker A, Wiethoff AJ, et al.: In vivo magnetic resonance imaging of coronary thrombosis using a fibrin-binding molecular magnetic resonance contrast agent. Circulation 2004, 110: 1463-1466.
44. Sirol M, Aguinaldo JG, Graham PB, et al.: Fibrin-targeted contrast agent for improvement of in vivo acute thrombus detection with magnetic resonance imaging. Atherosclerosis 2005, 182: 79-85.
45. Sirol M, Fuster V, Badimon JJ, et al.: Chronic thrombus detection with in vivo magnetic resonance imaging and a fibrin-targeted contrast agent. Circulation 2005, 112: 1594-1600.
46. Flacke S, Fischer S, Scott MJ, et al.: Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation 2001, 104: 1280-1285.
47. Morawski AM, Winter PM, Yu X, et al.: Quantitative "magnetic resonance immunohistochemistry" with ligand-targeted (19)F nanoparticles. Magn Reson Med 2004, 52: 1255-1262.
48. • Spuentrup E, Botnar RM, Wiethoff AJ, et al.: MR imaging of thrombi using EP-2104R, a fibrin-specific contrast agent: initial results in patients. Eur Radiol 2008, 18: 1995-2005. This article illustrates a molecular magnetic resonance technique that has been translated from in vitro/animal work to a human study. Most techniques, as illustrated by this article, are still in the early stages of investigation.
49. Miserus RJ, Herias MV, Prinzen L, et al.: Molecular MRI of early thrombus formation using a bimodal alpha2-antiplasmin-based contrast agent. JACC Cardiovasc Imaging 2009, 2: 987-996.
50. Chaubet F, Bertholon I, Serfaty JM, et al.: A new macromolecular paramagnetic MR contrast agent binds to activated human platelets. Contrast Media Mol Imaging 2007, 2: 178-188.